drugset / Trial / NCT05168683

Scintigraphy Study in Healthy Volunteers to Characterize the Performance of ALLN-346 Tablets

NCT05168683 ↗

Phase 1 Completed 12 enrolled Allena Pharmaceuticals BDD Pharma Ltd · collab
Non-randomizedCrossoverOpen-labelOther

Summary

The purpose of the study is to understand the gastrointestinal transit time and disintegration behavior of the formulations in vivo in normal healthy volunteers when ALLN-346 formulations are given with light meal or in fasted or other fed states.

Timeline

Start
2022-01-11
Primary completion
2022-02-23
Completion
2022-02-23

Drugs

EvaluationDrugModalityDoseRoute
Subject ALLN-346 Protein / enzyme biologic — —

Indications